Blood: Long-term prognosis for children with malignant blood disease treated with HSCT

There are no prognosis statistics for patients who have reported a child hematopoietic stem cell transplant (HSCT) survivorIn this study, Hsiu-Ju Yen and others compared the prevalence of symptoms, health-related quality of life (HRQOL) and risk factors among adult survivors of hematologic malignancies who received HSCT in childhood with routine treatment and non-cancer control groupsfrom StSurvivors of childhood hematologic malignancies in Jude's Lifetime Cohortstudy study (HSCT group: 112 bits of (70% allogeneic, 30% self-contained); Chronic health conditions (CHCs) were verified through clinical evaluationmultivariate logical regression analysis showed that HSCT survivors had significantly higher rates of sensory, motor, lung, and memory symptoms and lower physical HRQOL scores than non-cancer control groupsThe prevalence of all symptoms of HSCT and routine treatment was similar to hrQOL scores, but the cumulative prevalence of specific symptoms in HSCT survivors was significantly higher, as was double vision, dry eyes, and visual difficulties when wearing glassesIn addition to pain and anxiety, the occurrence of organ-specific CHCs was significantly associated with a high prevalence of all symptoms in adult survivors of childhood cancerthis study found that patients with HSCT and survivors of malignant tumors in the blood system who were treated with routine treatment reported similar levels of prognostic impairment, but both groups reported poor prognosis compared to non-cancer controlIn all survivors of pediatric hematologic malignancies, patients reported adverse prognosis associated with the presence of CHCs, whether using traditional therapies or hematopoietic stem cell transplants